| 12.93 -0.19 (-1.45%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 15.52 | 1-year : | 18.13 |
| Resists | First : | 13.28 | Second : | 15.52 |
| Pivot price | 12.62  |
|||
| Supports | First : | 12.56 | Second : | 12.1 |
| MAs | MA(5) : | 12.87 |
MA(20) : | 12.59 |
| MA(100) : | 9.09 |
MA(250) : | 0 | |
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 82 |
D(3) : | 83.9 |
| RSI | RSI(14): 67 |
|||
| 52-week | High : | 13.28 | Low : | 3.55 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ATXS ] has closed below upper band by 17.0%. Bollinger Bands are 47.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.19 - 13.27 | 13.27 - 13.34 |
| Low: | 12.67 - 12.75 | 12.75 - 12.82 |
| Close: | 12.81 - 12.94 | 12.94 - 13.06 |
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Sun, 07 Dec 2025
Panagora Asset Management Inc. Purchases New Holdings in Astria Therapeutics, Inc. $ATXS - MarketBeat
Thu, 04 Dec 2025
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Wed, 03 Dec 2025
Astria Therapeutics (ATXS) Acquisition Moves Forward with Antitr - GuruFocus
Sun, 30 Nov 2025
Astria Therapeutics: Updating Target Price, BioCryst Deal Expected To Go Through, Hold - Seeking Alpha
Wed, 12 Nov 2025
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - Business Wire
Wed, 12 Nov 2025
Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 4.206e+007 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 4,020 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 830.5 % |
| Return on Equity (ttm) | -27 % |
| Qtrly Rev. Growth | 706000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -539.38 |
| EBITDA (p.s.) | 8.825e+006 |
| Qtrly Earnings Growth | -2.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -120 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 0.42 |
| Dividend | 0 |
| Forward Dividend | 5.09e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|